293 related articles for article (PubMed ID: 26081617)
1. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Saleh EM
Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.
Todorovic V; Prevc A; Zakelj MN; Savarin M; Brozic A; Groselj B; Strojan P; Cemazar M; Sersa G
Radiat Oncol; 2019 Nov; 14(1):214. PubMed ID: 31775835
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
4. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide.
Giocanti N; Hennequin C; Balosso J; Mahler M; Favaudon V
Cancer Res; 1993 May; 53(9):2105-11. PubMed ID: 8386982
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIα levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer.
Bryant PE; Riches AC; Shovman O; Dewar JA; Adamson DJ
Mutagenesis; 2012 Nov; 27(6):737-41. PubMed ID: 22935224
[TBL] [Abstract][Full Text] [Related]
6. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
7. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
[TBL] [Abstract][Full Text] [Related]
8. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
9. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
10. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Kang K; Nho CW; Kim ND; Song DG; Park YG; Kim M; Pan CH; Shin D; Oh SH; Oh HS
Int J Oncol; 2014 Aug; 45(2):558-66. PubMed ID: 24841075
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
13. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
14. The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation.
Goswami PC; Roti Roti JL; Hunt CR
Mol Cell Biol; 1996 Apr; 16(4):1500-8. PubMed ID: 8657123
[TBL] [Abstract][Full Text] [Related]
15. Radioresistance in a human laryngeal squamous cell carcinoma cell line is associated with DNA methylation changes and topoisomerase II α.
Kim JS; Kim SY; Lee M; Kim SH; Kim SM; Kim EJ
Cancer Biol Ther; 2015; 16(4):558-66. PubMed ID: 25719218
[TBL] [Abstract][Full Text] [Related]
16. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
18. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
20. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
Gibson EG; King MM; Mercer SL; Deweese JE
Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
